ZNF322 and lung cancer: To ascertain the stimulatory effect of ZNF322A on lung cancer in the IRS1/PI3K/AKT pathway, we further analyzed IRS1 and AKT expressions of ZNF322A-silenced A549 cells at 48 h post-transfection by immunoblotting (Fig. 4e).